Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oteseconazole for recurrent vulvovaginal candidiasis
2018-001269-18Phase 3Completed
- Sponsor
- Mycovia Pharmaceuticals
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in recurrent vulvovaginal candidiasis (RVVC) and vulvovaginal candidiasis (VVC) comparing Oteseconazole with Placebo (2 arms). Primary endpoint: Proportion of subjects with one or more culture-verified acute vulvovaginal candidiasis episodes during the Maintenance Phase through Week 48. Started Oct 2018; status: completed.
02
Drugs
oteseconazole
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on 2018-001269-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001269-18.